Personalized Health and Related Technologies (PHRT) is a strategic focus area of the ETH Domain which encompasses six Swiss institutions: ETHZ, EPFL, PSI, Empa, Eawag and WSL. The main goal of PHRT is to drive the ongoing life science revolution that will ultimately transform medicine as it is today into ‘individualized medicine’. In essence, a person’s unique biological makeup will guide decisions on how to maintain and restore health. Thanks to its community of researchers and associated hospitals, PHRT is pushing the frontiers of knowledge on the mechanisms of diseases and opening the door to new treatments and technologies improving health and disease treatments.
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of
Following a highly competitive selection process by an international review panel, the PHRT Executive Committee has chosen two pioneering clinical trial projects from the ETH domain, in collaboration with clinical
On April 20, 2023, researchers from ETH Zurich and the University Hospitals of Zurich had a publi-cation released in Nature Cancer. Their work on multiple myeloma, a blood cancer, is
